Posts
A study comparing the use of HIV
integrase inhibitors in treatment-experienced people has shown that
dolutegravir has superior virological efficacy to raltegravir.
The phase 3 study involved 724
people who needed to change their treatment because their HIV was no longer
being suppressed.
They were randomized to receive
therapy based on either the new integrase inhibitor dolutegravir or raltegravir
(Isentress) in combination with other antiretroviral drugs.
Dolutegravir is taken once daily
whereas raltegravir requires twice-daily dosing.
After 48 weeks of therapy, 71% of
people taking dolutegravir had an undetectable viral load, compared to 63% of
those treated with raltegravir.
Virological failure – a viral load
which was never suppressed or has rebounded – was seen in 6% of people on
dolutegravir, compared to 12% of those on raltegravir. Looking only at
participants with a high baseline viral load (above 100,000 copies/ml), the
study found that 62% of people in the dolutegravir arm achieved an undetectable
viral load, compared to 47% of people in the raltegravir arm.
Both drugs had a similar safety
profile. Dolutegravir is expected to be licensed in the US and Europe later
this year.
The Friends of AIDS Foundation is
dedicated to enhancing the quality of life for HIV positive individuals and
empowering people to make healthy choices to prevent the spread of the HIV
virus.
To learn more about The Friends of
AIDS Foundation, please visit: http://www.friendsofaids.org.
TOGETHER WE REMAIN STRONG!
